Literature DB >> 11352772

Urocortin in the synovial tissue of patients with rheumatoid arthritis.

M Uzuki1, H Sasano, Y Muramatsu, K Totsune, K Takahashi, Y Oki, K Iino, T Sawai.   

Abstract

Urocortin is a newly identified member of the corticotropin-releasing factor (CRF) neuropeptide family, and is known to be involved in the modulation of the inflammatory process. We examined the expression of urocortin, CRF and their receptors (CRF receptor; CRF-R) in the synovial tissue of patients with rheumatoid arthritis (RA) in order to study the possible biological roles of urocortin. Synovial tissues/fluids were obtained from 38 patients with RA, nine patients with osteoarthritis and four with trauma. We studied the concentration of urocortin in the synovial fluid using RIA, and the expression of urocortin in synovial tissue using immunohistochemistry, mRNA in situ hybridization and reverse transcriptase-PCR (RT-PCR). In addition, we examined the immunolocalization of CRF and the expression of CRF-R1, -R2-alpha and -R2-beta mRNAs utilizing RT-PCR in these synovial tissues. Urocortin concentrations in synovial fluid were higher in RA patients (79.8+/-154 pg/ml) than in control patients (12.3+/-4.8 pg/ml; P< or =0.05). Urocortin immunoreactivity and mRNA signals were both detected in synovial cells, lymphocytes, fibroblasts and macrophages. The number of urocortin-positive cells in the synovium was significantly higher in RA (73.1+/-32.1 cells per high-power field) than in control (18.4+/-10.4 cells per high-power field) patients. In addition, both urocortin immunoreactivity and mRNA signals in the synovium reached maximum levels in the active stage of RA inflammation. Moreover, the number of immunoreactive urocortin-positive cells was significantly correlated with the urocortin concentration in synovial fluid (r=0.705; P<0.001) and with histologically defined local inflammatory activity (r=0.641; P<0.001). The distribution and number of immunoreactive CRF-positive cells in synovial tissue were similar to those of urocortin-positive cells (r=0.701; P<0.001). Urocortin, CRF-R1 and CRF-R2-alpha mRNAs detected by RT-PCR were expressed in in the synovium of 10/10, 10/10 and 2/10 RA patients respectively, but CRF-R2-beta was not expressed. Urocortin was actively synthesized in the synovium of RA patients. The present study suggests that urocortin may play an important role as an autocrine and/or paracrine regulator of synovial inflammation in RA.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11352772

Source DB:  PubMed          Journal:  Clin Sci (Lond)        ISSN: 0143-5221            Impact factor:   6.124


  14 in total

1.  Corticotropin Releasing Factor (CRF) activation of NF-kappaB-directed transcription in leukocytes.

Authors:  Eric M Smith; Mike Gregg; Farhad Hashemi; Liesl Schott; Thomas K Hughes
Journal:  Cell Mol Neurobiol       Date:  2006-04-22       Impact factor: 5.046

Review 2.  Physiology, pharmacology, and therapeutic relevance of urocortins in mammals: ancient CRF paralogs.

Authors:  Eva M Fekete; Eric P Zorrilla
Journal:  Front Neuroendocrinol       Date:  2006-11-02       Impact factor: 8.606

Review 3.  Human umbilical cord blood-derived mast cells: a unique model for the study of neuro-immuno-endocrine interactions.

Authors:  T C Theoharides; D Kempuraj; M Tagen; M Vasiadi; C L Cetrulo
Journal:  Stem Cell Rev       Date:  2006       Impact factor: 5.739

4.  Neuropeptides rescue mice from lethal sepsis by down-regulating secretion of the late-acting inflammatory mediator high mobility group box 1.

Authors:  Alejo Chorny; Mario Delgado
Journal:  Am J Pathol       Date:  2008-04-01       Impact factor: 4.307

5.  Corticotropin-releasing factor receptor subtype 2 in human colonic mucosa: down-regulation in ulcerative colitis.

Authors:  Ekaterini Chatzaki; Peter A Anton; Mulugeta Million; Maria Lambropoulou; Theodoros Constantinidis; George Kolios; Yvette Taché; Dimitri E Grigoriadis
Journal:  World J Gastroenterol       Date:  2013-03-07       Impact factor: 5.742

6.  Upregulation of ANK protein expression in joint tissue in calcium pyrophosphate dihydrate crystal deposition disease.

Authors:  Miwa Uzuki; Takashi Sawai; Lawrence M Ryan; Ann K Rosenthal; Ikuko Masuda
Journal:  J Rheumatol       Date:  2013-12-01       Impact factor: 4.666

7.  Urocortin promotes the development of vasculitis in a rat model of thromboangiitis obliterans via corticotrophin-releasing factor type 1 receptors.

Authors:  Youhua Xu; Rongjian Zhang; Jie Chen; Qichun Zhang; Juejin Wang; Jue Hu; Xiaowei Guan; Lai Jin; Hong Fu; Bo Gui; Yuanyuan Guo; Shengnan Li
Journal:  Br J Pharmacol       Date:  2009-06-30       Impact factor: 8.739

8.  Footshock-induced urinary bladder hypersensitivity: role of spinal corticotropin-releasing factor receptors.

Authors:  Meredith T Robbins; Timothy J Ness
Journal:  J Pain       Date:  2008-07-16       Impact factor: 5.820

9.  Cardiomyocyte-specific overexpression of HEXIM1 prevents right ventricular hypertrophy in hypoxia-induced pulmonary hypertension in mice.

Authors:  Noritada Yoshikawa; Noriaki Shimizu; Takako Maruyama; Motoaki Sano; Tomohiro Matsuhashi; Keiichi Fukuda; Masaharu Kataoka; Toru Satoh; Hidenori Ojima; Takashi Sawai; Chikao Morimoto; Akiko Kuribara; Osamu Hosono; Hirotoshi Tanaka
Journal:  PLoS One       Date:  2012-12-31       Impact factor: 3.240

Review 10.  Urocortin-like immunoreactivity in the primary lymphoid organs of the duck (Anas platyrhynchos).

Authors:  A De Luca; C Squillacioti; M E Pero; S Paino; E Langella; N Mirabella
Journal:  Eur J Histochem       Date:  2009-09-30       Impact factor: 3.188

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.